Journals By Industry - Cancer Drugs

CGEN-15001, CGEN-15021 and CGEN-15091 are predicted B7/CD28-like proteins discovered using the company's Protein Family Members Discovery Platform. The company reported that in the collagen induced arthritis model of RA, treatments with either CGEN-15001...

ABSTRACT Despite the prevalence of women caring for stroke survivors, relatively little research has focused specifically on the experience and needs of informal female caregivers of stroke survivors. Therefore, the purpose of this...

The company has also announced the assignment of US co-promotion rights to AQUORAL, an FDA-cleared, prescription-only spray for the treatment of Xerostomia, or the medical term for dry mouth due to a lack...

In the Phase I trial, newly diagnosed patients are enrolled to one of two regimens evaluating ADCETRIS administered either sequentially with CHOP or concurrently with CH-P, which removes vincristine from the regimen: The...

The study has enrolled 41 patients who progressed on at least one prior chemotherapy regimen that included a platinum compound, or cisplatin, oxaliplatin, or carboplatin, and a fluoropyrimidine compound, or 5-fluorouracil [5-FU] or...

The week 12 disease control rate (PR and SD at week 12) was 68%. Evidence of objective tumor regression was observed in 78% of patients, including those with or without prior sorafenib therapy....

Last January Marc Alessi was tapped to lead the Long Island Angel Network as it sought to help finance startups that would hopefully grow to become the region's largest corporations. Now he has...

Stony Brook University has entered into a multiyear research partnership with the global pharmaceutical company Sanofi to develop a potential treatment for tuberculosis and other bacterial infections. The university didn't disclose the terms...

-- Test Associated with Changes in Treatment Management in 65% of Patients with Difficult-to-Diagnose Cancers -- REDWOOD CITY, Calif. -- Pathwork Diagnostics, Inc., a pioneer in creating genomics-based diagnostics in oncology utilizing their...

DUBLIN -- Research and Markets(http://www.researchandmarkets.com/research/657030/brain_cancer_globa) has announced the addition of GlobalData's new report "Brain Cancer Global Clinical Trials Review, H2, 2011" to their offering. GlobalData's clinical trial report, Brain Cancer Global Clinical Trials...

DUBLIN -- Research and Markets(http://www.researchandmarkets.com/research/ff135e/cervical_cancer_gl) has announced the addition of GlobalData 's new report "Cervical Cancer Global Clinical Trials Review, H2, 2011" to their offering. GlobalData's clinical trial report, Cervical Cancer Global Clinical...

ROCKVILLE, Md. -- Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing oncology and CNS therapeutics, today announced that it has secured Hungarian Regulatory Authority and Ethics Committee...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/2c0db2/market_and_product) has announced the addition of the "Market and Product Forecasts: Top 20 Oncology Therapy Brands - The value of the top 20 decreases as the oncology market...

SHEFFIELD, England -- Simcyp Limited, the leader in modelling and simulation of drug-drug interactions in virtual human populations, today announces it has extended its animal models to include a virtual mouse. Laboratory mice...

BALERNA, Switzerland -- APR Applied Pharma Research s.a. ("APR"), Labtec GmbH ("Labtec") and Norgine BV ("Norgine") announce the signature of an exclusive licensing agreement under which Norgine will market and distribute Setofilm[TM] Ondansetron...

- Additional End-of-Phase 2 Meeting Not Required- -Company to Submit for Special Protocol Assessment- KNOXVILLE, Tenn. -- Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, has received guidance...

Professors David Kerr and Nick La Thangue offer oncology consulting and biomarker R&D activities spun out from the University of Oxford OXFORD, U.K. & RESEARCH TRIANGLE PARK, N.C. -- Continuing its commitment to...

WALTHAM, Mass. -- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, January...

NEEDHAM, Mass. -- Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that it will host a research and development day for the investment community on Monday, January 23, 2012 at 8:30 am Eastern Time....